103 related articles for article (PubMed ID: 34047449)
21. A Randomized Crossover Trial to Compare Automated Insulin Delivery (the Artificial Pancreas) With Carbohydrate Counting or Simplified Qualitative Meal-Size Estimation in Type 1 Diabetes.
Haidar A; Legault L; Raffray M; Gouchie-Provencher N; Jafar A; Devaux M; Ghanbari M; Rabasa-Lhoret R
Diabetes Care; 2023 Jul; 46(7):1372-1378. PubMed ID: 37134305
[TBL] [Abstract][Full Text] [Related]
22. The human amylin analog, pramlintide, corrects postprandial hyperglucagonemia in patients with type 1 diabetes.
Fineman MS; Koda JE; Shen LZ; Strobel SA; Maggs DG; Weyer C; Kolterman OG
Metabolism; 2002 May; 51(5):636-41. PubMed ID: 11979398
[TBL] [Abstract][Full Text] [Related]
23. Effect of 14 days' subcutaneous administration of the human amylin analogue, pramlintide (AC137), on an intravenous insulin challenge and response to a standard liquid meal in patients with IDDM.
Kolterman OG; Schwartz S; Corder C; Levy B; Klaff L; Peterson J; Gottlieb A
Diabetologia; 1996 Apr; 39(4):492-9. PubMed ID: 8778001
[TBL] [Abstract][Full Text] [Related]
24. Effects of the amylin analogue pramlintide on hepatic glucagon responses and intermediary metabolism in Type 1 diabetic subjects.
Orskov L; Nyholm B; Yde Hove K; Gravholt CH; Møller N; Schmitz O
Diabet Med; 1999 Oct; 16(10):867-74. PubMed ID: 10547215
[TBL] [Abstract][Full Text] [Related]
25. Home use of a bihormonal bionic pancreas versus insulin pump therapy in adults with type 1 diabetes: a multicentre randomised crossover trial.
El-Khatib FH; Balliro C; Hillard MA; Magyar KL; Ekhlaspour L; Sinha M; Mondesir D; Esmaeili A; Hartigan C; Thompson MJ; Malkani S; Lock JP; Harlan DM; Clinton P; Frank E; Wilson DM; DeSalvo D; Norlander L; Ly T; Buckingham BA; Diner J; Dezube M; Young LA; Goley A; Kirkman MS; Buse JB; Zheng H; Selagamsetty RR; Damiano ER; Russell SJ
Lancet; 2017 Jan; 389(10067):369-380. PubMed ID: 28007348
[TBL] [Abstract][Full Text] [Related]
26. Day and night glycaemic control with a bionic pancreas versus conventional insulin pump therapy in preadolescent children with type 1 diabetes: a randomised crossover trial.
Russell SJ; Hillard MA; Balliro C; Magyar KL; Selagamsetty R; Sinha M; Grennan K; Mondesir D; Ekhlaspour L; Zheng H; Damiano ER; El-Khatib FH
Lancet Diabetes Endocrinol; 2016 Mar; 4(3):233-243. PubMed ID: 26850709
[TBL] [Abstract][Full Text] [Related]
27. "Learning" Can Improve the Blood Glucose Control Performance for Type 1 Diabetes Mellitus.
Wang Y; Zhang J; Zeng F; Wang N; Chen X; Zhang B; Zhao D; Yang W; Cobelli C
Diabetes Technol Ther; 2017 Jan; 19(1):41-48. PubMed ID: 28060528
[TBL] [Abstract][Full Text] [Related]
28. Assessing the efficacy, safety and utility of 6-month day-and-night automated closed-loop insulin delivery under free-living conditions compared with insulin pump therapy in children and adolescents with type 1 diabetes: an open-label, multicentre, multinational, single-period, randomised, parallel group study protocol.
Musolino G; Allen JM; Hartnell S; Wilinska ME; Tauschmann M; Boughton C; Campbell F; Denvir L; Trevelyan N; Wadwa P; DiMeglio L; Buckingham BA; Weinzimer S; Acerini CL; Hood K; Fox S; Kollman C; Sibayan J; Borgman S; Cheng P; Hovorka R
BMJ Open; 2019 Jun; 9(6):e027856. PubMed ID: 31164368
[TBL] [Abstract][Full Text] [Related]
29. Infusion of pramlintide, a human amylin analogue, delays gastric emptying in men with IDDM.
Kong MF; King P; Macdonald IA; Stubbs TA; Perkins AC; Blackshaw PE; Moyses C; Tattersall RB
Diabetologia; 1997 Jan; 40(1):82-8. PubMed ID: 9028722
[TBL] [Abstract][Full Text] [Related]
30. Safety, efficacy and glucose turnover of reduced prandial boluses during closed-loop therapy in adolescents with type 1 diabetes: a randomized clinical trial.
Elleri D; Biagioni M; Allen JM; Kumareswaran K; Leelarathna L; Caldwell K; Nodale M; Wilinska ME; Haidar A; Calhoun P; Kollman C; Jackson NC; Umpleby AM; Acerini CL; Dunger DB; Hovorka R
Diabetes Obes Metab; 2015 Dec; 17(12):1173-9. PubMed ID: 26257323
[TBL] [Abstract][Full Text] [Related]
31. Artificial Pancreas: Evaluating the ARG Algorithm Without Meal Announcement.
Fushimi E; Colmegna P; De Battista H; Garelli F; Sánchez-Peña R
J Diabetes Sci Technol; 2019 Nov; 13(6):1035-1043. PubMed ID: 31339059
[TBL] [Abstract][Full Text] [Related]
32. Pramlintide reduces postprandial glucose excursions when added to insulin lispro in subjects with type 2 diabetes: a dose-timing study.
Maggs DG; Fineman M; Kornstein J; Burrell T; Schwartz S; Wang Y; Ruggles JA; Kolterman OG; Weyer C
Diabetes Metab Res Rev; 2004; 20(1):55-60. PubMed ID: 14737746
[TBL] [Abstract][Full Text] [Related]
33. The amylin analog pramlintide improves glycemic control and reduces postprandial glucagon concentrations in patients with type 1 diabetes mellitus.
Nyholm B; Orskov L; Hove KY; Gravholt CH; Møller N; Alberti KG; Moyses C; Kolterman O; Schmitz O
Metabolism; 1999 Jul; 48(7):935-41. PubMed ID: 10421239
[TBL] [Abstract][Full Text] [Related]
34. Comparison of dual-hormone artificial pancreas, single-hormone artificial pancreas, and conventional insulin pump therapy for glycaemic control in patients with type 1 diabetes: an open-label randomised controlled crossover trial.
Haidar A; Legault L; Messier V; Mitre TM; Leroux C; Rabasa-Lhoret R
Lancet Diabetes Endocrinol; 2015 Jan; 3(1):17-26. PubMed ID: 25434967
[TBL] [Abstract][Full Text] [Related]
35. Impact of pramlintide on glucose fluctuations and postprandial glucose, glucagon, and triglyceride excursions among patients with type 1 diabetes intensively treated with insulin pumps.
Levetan C; Want LL; Weyer C; Strobel SA; Crean J; Wang Y; Maggs DG; Kolterman OG; Chandran M; Mudaliar SR; Henry RR
Diabetes Care; 2003 Jan; 26(1):1-8. PubMed ID: 12502651
[TBL] [Abstract][Full Text] [Related]
36. The challenges of achieving postprandial glucose control using closed-loop systems in patients with type 1 diabetes.
Gingras V; Taleb N; Roy-Fleming A; Legault L; Rabasa-Lhoret R
Diabetes Obes Metab; 2018 Feb; 20(2):245-256. PubMed ID: 28675686
[TBL] [Abstract][Full Text] [Related]
37. Post-breakfast closed-loop glucose control is improved when accompanied with carbohydrate-matching bolus compared to weight-dependent bolus.
Haidar A; Farid D; St-Yves A; Messier V; Chen V; Xing D; Brazeau AS; Duval C; Boulet B; Legault L; Rabasa-Lhoret R
Diabetes Metab; 2014 Jun; 40(3):211-4. PubMed ID: 24656963
[TBL] [Abstract][Full Text] [Related]
38. Artificial Pancreas: Clinical Study in Latin America Without Premeal Insulin Boluses.
Sánchez-Peña R; Colmegna P; Garelli F; De Battista H; García-Violini D; Moscoso-Vásquez M; Rosales N; Fushimi E; Campos-Náñez E; Breton M; Beruto V; Scibona P; Rodriguez C; Giunta J; Simonovich V; Belloso WH; Cherñavvsky D; Grosembacher L
J Diabetes Sci Technol; 2018 Sep; 12(5):914-925. PubMed ID: 29998754
[TBL] [Abstract][Full Text] [Related]
39. Efficacy of dual-hormone artificial pancreas to alleviate the carbohydrate-counting burden of type 1 diabetes: A randomized crossover trial.
Gingras V; Rabasa-Lhoret R; Messier V; Ladouceur M; Legault L; Haidar A
Diabetes Metab; 2016 Feb; 42(1):47-54. PubMed ID: 26072052
[TBL] [Abstract][Full Text] [Related]
40. Realizing a Closed-Loop (Artificial Pancreas) System for the Treatment of Type 1 Diabetes.
Lal RA; Ekhlaspour L; Hood K; Buckingham B
Endocr Rev; 2019 Dec; 40(6):1521-1546. PubMed ID: 31276160
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
